Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368936 | 0.86 | CDK2 (0.42) | NR1H2CCNA2CDK2CCNA1C5AR1 | |
| SCHEMBL16627099 | 0.71 | CDK2 (0.43) | NR1H2CCNA2CDK2CCNA1C5AR1 | |
| SCHEMBL2915130 | 0.70 | NR1H2 (0.40) | NR1H2ADORA1NAMPT | |
| SCHEMBL1888941 | 0.68 | ADORA1 (0.47) | NR1H2ADORA1KDM4E | |
| SCHEMBL6375680 | 0.68 | C5AR1 (0.35) | NR1H2CCNA2CDK2CCNA1ADORA1 | |
| SCHEMBL17317969 | 0.68 | ADORA1 (0.50) | NR1H2ADORA1KDM4E | |
| SCHEMBL22095959 | 0.66 | C5AR1 (0.39) | NR1H2CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL26407436 | 0.65 | NR1H2 (0.35) | NR1H2CCNA2CDK2CCNA1ADORA1 | |
| SCHEMBL19195046 | 0.65 | NR1H2 (0.38) | NR1H2JAK3CCNA2CDK2CCNA1 | |
| SCHEMBL6440183 | 0.65 | ADORA1 (0.36) | NR1H2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NR1H2 2934/4885JAK3 396/4885GRIN2B 3938/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NR1H2 2934/4885JAK3 396/4885GRIN2B 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.